Tumour necrosis factor antagonists: structure, function, and tuberculosis risks

The Lancet Infectious Diseases

Volumn 8, Issue 10, 2008, Pages 601-611

  Wallis, Robert S ^a,b  

^a Pharmaceutical Product Development   (United States)

^b PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; CERTOLIZUMAB PEGOL; ETANERCEPT; INFLIXIMAB; ISONIAZID; LYMPHOTOXIN; PLACEBO; PYRAZINAMIDE; RIFAMPICIN; TUMOR NECROSIS FACTOR ANTIBODY; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RECEPTOR 2;

APOPTOSIS; ASPERGILLOSIS; BARTONELLOSIS; BINDING KINETICS; BIOLOGY; CANDIDIASIS; CLINICAL TRIAL; COCCIDIOIDOMYCOSIS; COMPREHENSION; CRYPTOCOCCOSIS; CYTOTOXICITY; HISTOPLASMOSIS; HUMAN; INFECTION PREVENTION; INTROSPECTION; LEGIONNAIRE DISEASE; LEPROSY; LISTERIOSIS; LIVER TOXICITY; MYCOBACTERIOSIS; NOCARDIOSIS; NONHUMAN; PNEUMOCYSTOSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STRUCTURE; REVIEW; RISK; SALMONELLOSIS; STOICHIOMETRY; T LYMPHOCYTE ACTIVATION; TOXOPLASMOSIS; TUBERCULOSIS;

ANTIBODIES, MONOCLONAL; HUMANS; IMMUNOLOGIC FACTORS; RISK FACTORS; STRUCTURE-ACTIVITY RELATIONSHIP; TUBERCULOSIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 52049124279     PISSN: 14733099     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1473-3099(08)70227-5     Document Type: Review

References (125)

1. Gardam M.A., Keystone E.C., Menzies R., et al. Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management. Lancet Infect Dis 3 (2003) 148-155
2. Wajant H., Pfizenmaier K., and Scheurich P. Tumor necrosis factor signaling. Cell Death Differ 10 (2003) 45-65
3. Hehlgans T., and Pfeffer K. The intriguing biology of the tumour necrosis factor/tumour necrosis factor receptor superfamily: players, rules and the games. Immunology 115 (2005) 1-20
4. Baud V., and Karin M. Signal transduction by tumor necrosis factor and its relatives. Trends Cell Biol 11 (2001) 372-377
5. Kriegler M., Perez C., DeFay K., Albert I., and Lu S.D. A novel form of TNF/cachectin is a cell surface cytotoxic transmembrane protein: ramifications for the complex physiology of TNF. Cell 53 (1988) 45-53
6. Black R.A., Rauch C.T., Kozlosky C.J., et al. A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells. Nature 385 (1997) 729-733
7. Eck M.J., and Sprang S.R. The structure of tumor necrosis factor-alpha at 2.6 A resolution. Implications for receptor binding. J Biol Chem 264 (1989) 17595-17605
8. Aversa G., Punnonen J., and De Vries J.E. The 26-kD transmembrane form of tumor necrosis factor alpha on activated CD4+ T cell clones provides a costimulatory signal for human B cell activation. J Exp Med 177 (1993) 1575-1585
9. Harashima S., Horiuchi T., Hatta N., et al. Outside-to-inside signal through the membrane TNF-alpha induces E-selectin (CD62E) expression on activated human CD4+ T cells. J Immunol 166 (2001) 130-136
10. Mitoma H., Horiuchi T., Hatta N., et al. Infliximab induces potent anti-inflammatory responses by outside-to-inside signals through transmembrane TNF-alpha. Gastroenterology 128 (2005) 376-392
11. Pfeffer K., Matsuyama T., Kundig T.M., et al. Mice deficient for the 55 kd tumor necrosis factor receptor are resistant to endotoxic shock, yet succumb to L monocytogenes infection. Cell 73 (1993) 457-467
12. Peschon J.J., Torrance D.S., Stocking K.L., et al. TNF receptor-deficient mice reveal divergent roles for p55 and p75 in several models of inflammation. J Immunol 160 (1998) 943-952
13. Grell M., Douni E., Wajant H., et al. The transmembrane form of tumor necrosis factor is the prime activating ligand of the 80 kDa tumor necrosis factor receptor. Cell 83 (1995) 793-802
14. Pfeffer K. Biological functions of tumor necrosis factor cytokines and their receptors. Cytokine Growth Factor Rev 14 (2003) 185-191
15. Roach D.R., Bean A.G., Demangel C., France M.P., Briscoe H., and Britton W.J. TNF regulates chemokine induction essential for cell recruitment, granuloma formation, and clearance of mycobacterial infection. J Immunol 168 (2002) 4620-4627
16. Flynn J.L., Goldstein M.M., Chan J., et al. Tumor necrosis factor-alpha is required in the protective immune response against Mycobacterium tuberculosis in mice. Immunity 2 (1995) 561-572
17. Mohan V.P., Scanga C.A., Yu K., et al. Effects of tumor necrosis factor alpha on host immune response in chronic persistent tuberculosis: possible role for limiting pathology. Infect Immun 69 (2001) 1847-1855
18. Bean A.G., Roach D.R., Briscoe H., et al. Structural deficiencies in granuloma formation in TNF gene-targeted mice underlie the heightened susceptibility to aerosol Mycobacterium tuberculosis infection, which is not compensated for by lymphotoxin. J Immunol 162 (1999) 3504-3511
19. Flynn J.L., Chan J., Triebold K.J., Dalton D.K., Stewart T.A., and Bloom B.R. An essential role for interferon gamma in resistance to Mycobacterium tuberculosis infection. J Exp Med 178 (1993) 2249-2254
20. Saunders B.M., Tran S., Ruuls S., Sedgwick J.D., Briscoe H., and Britton W.J. Transmembrane TNF is sufficient to initiate cell migration and granuloma formation and provide acute, but not long-term, control of Mycobacterium tuberculosis infection. J Immunol 174 (2005) 4852-4859
21. Erickson S.L., de Sauvage F.J., Kikly K., et al. Decreased sensitivity to tumour-necrosis factor but normal T-cell development in TNF receptor-2-deficient mice. Nature 372 (1994) 560-633
22. Everest P., Roberts M., and Dougan G. Susceptibility to Salmonella typhimurium infection and effectiveness of vaccination in mice deficient in the tumor necrosis factor alpha p55 receptor. Infect Immun 66 (1998) 3355-3364
23. Rothe J., Lesslauer W., Lotscher H., et al. Mice lacking the tumour necrosis factor receptor 1 are resistant to TNF-mediated toxicity but highly susceptible to infection by Listeria monocytogenes. Nature 364 (1993) 798-802
24. Ehlers S., Holscher C., Scheu S., et al. The lymphotoxin beta receptor is critically involved in controlling infections with the intracellular pathogens Mycobacterium tuberculosis and Listeria monocytogenes. J Immunol 170 (2003) 5210-5218
25. Roach D.R., Briscoe H., Saunders B., France M.P., Riminton S., and Britton W.J. Secreted lymphotoxin-alpha is essential for the control of an intracellular bacterial infection. J Exp Med 193 (2001) 239-246
26. Bopst M., Garcia I., Guler R., et al. Differential effects of TNF and LTalpha in the host defense against M bovis BCG. Eur J Immunol 31 (2001) 1935-1943
27. Jacobs M., Brown N., Allie N., and Ryffel B. Fatal Mycobacterium bovis BCG infection in TNF-LT-alpha-deficient mice. Clin Immunol 94 (2000) 192-199
28. Olleros M.L., Guler R., Vesin D., et al. Contribution of transmembrane tumor necrosis factor to host defense against Mycobacterium bovis bacillus Calmette-guerin and Mycobacterium tuberculosis infections. Am J Pathol 166 (2005) 1109-1120
29. Olleros M.L., Guler R., Corazza N., et al. Transmembrane TNF induces an efficient cell-mediated immunity and resistance to Mycobacterium bovis bacillus Calmette-Guerin infection in the absence of secreted TNF and lymphotoxin-alpha. J Immunol 168 (2002) 3394-3401
30. Alexopoulou L., Kranidioti K., Xanthoulea S., et al. Transmembrane TNF protects mutant mice against intracellular bacterial infections, chronic inflammation and autoimmunity. Eur J Immunol 36 (2006) 2768-2780
31. Musicki K., Briscoe H., Tran S., Britton W.J., and Saunders B.M. Differential requirements for soluble and transmembrane tumor necrosis factor in the immunological control of primary and secondary Listeria monocytogenes infection. Infect Immun 74 (2006) 3180-3189
32. Torres D., Janot L., Quesniaux V.F., et al. Membrane tumor necrosis factor confers partial protection to listeria infection. Am J Pathol 167 (2005) 1677-1687
33. Abbott Laboratories. Humira prescribing information, 2007. Abbott Park, IL, USA: Abbott Laboratories. http://www.rxabbott.com/pdf/humira.pdf (accessed Aug 13, 2008).
34. Centocor. Infliximab (Remicade) prescribing information (2007), Centocor, Malvern PA, USA. http://www.remicade.com/remicade/assets/HCP_PPI.pdf (accessed Aug 13, 2008).
35. Baughman R.P., Drent M., Kavuru M., et al. Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement. Am J Respir Crit Care Med 174 (2006) 795-802
36. Saleh S., Ghodsian S., Yakimova V., Henderson J., and Sharma O.P. Effectiveness of infliximab in treating selected patients with sarcoidosis. Respir Med 100 (2006) 2053-2059
37. Rossman M.D., Newman L.S., Baughman R.P., et al. A double-blinded, randomized, placebo-controlled trial of infliximab in subjects with active pulmonary sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 23 (2006) 201-208
38. Sandborn W.J., Feagan B.G., Stoinov S., et al. Certolizumab pegol for the treatment of Crohn's disease. N Engl J Med 357 (2007) 228-238
39. Keystone E., Mason D., and Combe B. The anti-TNF certolizumab pegol in combination with methotrexate is significantly more effective than methotrexate alone in the treatment of patients with active rheumatoid arthritis: preliminary results from the RAPID 1 study. Ann Rheum Dis 66 suppl 2 (2007) 55
40. Smolen J., Brezezicki J., Mason D., and Kavanaugh A. Efficacy and safety of certolizumab pegol in combination with methotrexate (MTX) in patients with active rheumatoid arthritis despite MTX therapy: results from the RAPID 2 study. Ann Rheum Dis 66 suppl 2 (2007) 187
41. St Clair E.W., Wagner C.L., Fasanmade A.A., et al. The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 46 (2002) 1451-1459
42. Nestorov I. Clinical pharmacokinetics of TNF antagonists: how do they differ?. Semin Arthritis Rheum 34 (2005) 12-18
43. Amgen. Enbrel prescribing information (2005), Amgen and Wyeth Pharmaceuticals, Thousand Oaks, CA, and Madison, NJ, USA. http://www.enbrel.com/prescribing-information.jsp (accessed Aug 13, 2008).
44. Sandborn W.J., Hanauer S.B., Katz S., et al. Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology 121 (2001) 1088-1094
45. Utz J.P., Limper A.H., Kalra S., et al. Etanercept for the treatment of stage II and III progressive pulmonary sarcoidosis. Chest 124 (2003) 177-185
46. Wajdula J., Macpeek D., Lim S., Hamza S., and Fatenejad S. Incidence of tuberculosis is low in patients receiving etanercept therapy for the treatment of rheumatoid arthritis: results from a combined analysis of US and ex-US double-blind trials and their open label extensions. Ann Rheum Dis 66 suppl 2 (2007) 195
47. Infuso A., and Falzon D. European survey of BCG vaccination policies and surveillance in children, 2005. Euro Surveill 11 (2006) 6-11
48. WHO. Global tuberculosis control-surveillance, planning, financing (2007), World Health Organization, Geneva. http://www.who.int/tb/publications/global_report/2007/en/index.html (accessed Aug 13, 2008).
49. Jajosky R.A., Hall P.A., Adams D.A., et al. Summary of notifiable diseases-United States, 2004. MMWR Morb Mortal Wkly Rep 53 (2006) 1-79
50. Nardell E.A., and Wallis R.S. Here today-gone tomorrow: the case for transient acute tuberculosis infection. Am J Respir Crit Care Med 174 (2006) 734-735
51. Coaccioli S., Di Cato L., Marioli D., et al. Impaired cutaneous cell-mediated immunity in newly diagnosed rheumatoid arthritis. Panminerva Med 42 (2000) 263-266
52. Wallis R.S., Broder M.S., Wong J.Y., Hanson J.Y., and Beenhouwer D.O. Granulomatous infectious diseases associated with TNF antagonists. Clin Infect Dis 38 (2004) 1261-1265
53. Wallis R.S., Broder M.S., Wong J.Y., and Beenhouwer D.O. Granulomatous infections due to tumor necrosis factor blockade: correction. Clin Infect Dis 39 (2004) 1254-1256
54. Bergstrom L., Yocum D.E., Ampel N.M., et al. Increased risk of coccidioidomycosis in patients treated with TNF antagonists. Arthritis Rheum 50 (2004) 1959-1966
55. Brassard P., Kezouh A., and Suissa S. Antirheumatic drugs and the risk of tuberculosis. J Infect Dis 43 (2006) 1532-1537
56. Wallis R.S. Tumor necrosis factor-alpha inhibitors and mycobacterial infections. In: Rose B.D. (Ed). UpToDate (2008), UpToDate, Waltham, MA. http://www.uptodate.com (accessed Aug 29, 2008).
57. Wolfe F., Michaud K., Anderson J., and Urbansky K. Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapy. Arthritis Rheum 50 (2004) 372-379
58. Dixon W.G., Watson K., Lunt M., Hyrich K.L., Silman A.J., and Symmons D.P. Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 54 (2006) 2368-2376
59. Askling J., Fored C.M., Brandt L., et al. Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden. Arthritis Rheum 52 (2005) 1986-1992
60. Listing J., Strangfeld A., Kary S., et al. Infections in patients with rheumatoid arthritis treated with biologic agents. Arthritis Rheum 52 (2005) 3403-3412
61. Carmona L., Hernandez-Garcia C., Vadillo C., et al. Increased risk of tuberculosis in patients with rheumatoid arthritis. J Rheumatol 30 (2003) 1436-1439
62. Gomez-Reino J.J., Carmona L., Valverde V.R., Mola E.M., and Montero M.D. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. Arthritis Rheum 48 (2003) 2122-2127
63. Carmona L., Gomez-Reino J.J., Rodriguez-Valverde V., et al. Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists. Arthritis Rheum 52 (2005) 1766-1772
64. Fonseca J.E., Canhao H., and Silva C. Tuberculosis in rheumatic patients treated with tumour necrosis factor alpha antagonists: the Portuguese experience. Acta Reumatol Port 31 (2006) 247-253 (in Portuguese).
65. Salmon D, Tubach F, Ravaud P. A risk of tuberculosis persists in patients treated with anti TNF-a antagonist therapy despite prophylactic guidelines: identification of main risk factors. 17th European Congress of Clinical Microbiology and Infectious Diseases and 25th Interntational Congress of Chemotherapy; Munich, Germany; March 31-April 3, 2007. Abstract O471.
66. Tubach F., Salmon-Ceron D., Ravaud P., and Mariette X. The RATIO observatory: French registry of opportunistic infections, severe bacterial infections, and lymphomas complicating anti-TnFalpha therapy. Joint Bone Spine 72 (2005) 456-460
67. Keane J., Gershon S., Wise R.P., et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 345 (2001) 1098-1104
68. Mines D., and Novelli L. Antirheumatic drugs and the risk of tuberculosis. Clin Infect Dis 44 (2007) 619-620
69. Subramanyan G.S., Yokoe D.S., Sharnprapai S., Nardell E., McCray E., and Platt R. Using automated pharmacy records to assess the management of tuberculosis. Emerg Infect Dis 5 (1999) 788-791
70. Wallis R.S. Mathematical modeling of the cause of tuberculosis during tumor necrosis factor blockade. Arthritis Rheum 58 (2008) 947-952
71. Plessner H.L., Lin P.L., Kohno T., et al. Neutralization of tumor necrosis factor (TNF) by antibody but not TNF receptor fusion molecule exacerbates chronic murine tuberculosis. J Infect Dis 195 (2007) 1643-1650
72. Korth-Bradley J.M., Rubin A.S., Hanna R.K., Simcoe D.K., and Lebsack M.E. The pharmacokinetics of etanercept in healthy volunteers. Ann Pharmacother 34 (2000) 161-164
73. Nesbitt A.M., Gramlick A., Fossati G., Henry A.J., and Stephens P.E. Assessment of the affinity for soluble TNF and the neutralising potency against soluble and membrane TNF of the anti-TNF agents certolizumab pegol, adalimumab, etanercept and infliximab. Ann Rheum Dis 65 suppl 2 (2006) 456
74. Scallon B., Cai A., Solowski N., et al. Binding and functional comparisons of two types of tumor necrosis factor antagonists. J Pharmacol Exp Ther 301 (2002) 418-426
75. Santora L.C., Kaymakcalan Z., Sakorafas P., Krull I.S., and Grant K. Characterization of noncovalent complexes of recombinant human monoclonal antibody and antigen using cation exchange, size exclusion chromatography, and BIAcore. Anal Biochem 299 (2001) 119-129
76. Rigby W.F. Drug insight: different mechanisms of action of tumor necrosis factor antagonists-passive-aggressive behavior?. Nat Clin Pract Rheumatol 3 (2007) 227-233
77. Marcoux B.S., and De Bandt M. Vasculitides induced by TNFalpha antagonists: a study in 39 patients in France. Joint Bone Spine 73 (2006) 710-713
78. Mohan N., Edwards E.T., Cupps T.R., et al. Leukocytoclastic vasculitis associated with tumor necrosis factor-alpha blocking agents. J Rheumatol 31 (2004) 1955-1958
79. Nesbitt A.M., and Fossati G. In vitro complement-dependent cytotoxicity and antibody-dependent cellular cytotoxicity by the anti-TNF agents certolizumab pegol, adalimumab, etanercept, and infliximab. Ann Rheum Dis 65 suppl 2 (2006) 455
80. Scallon B.J., Moore M.A., Trinh H., Knight D.M., and Ghrayeb J. Chimeric anti-TNF-alpha monoclonal antibody cA2 binds recombinant transmembrane TNF-alpha and activates immune effector functions. Cytokine 7 (1995) 251-259
81. Saliu O., Sofer C., Stein D.S., Schwander S.K., and Wallis R.S. Tumor necrosis factor blockers: differential effects on mycobacterial immunity. J Infect Dis 194 (2006) 486-492
82. ten Hove T., van Montfrans C., Peppelenbosch M.P., and van Deventer S.J. Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn's disease. Gut 50 (2002) 206-211
83. Van den Brande J.M., Braat H., van den Brink G.R., et al. Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease. Gastroenterology 124 (2003) 1774-1785
84. Di Sabatino A., Ciccocioppo R., Cinque B., et al. Defective mucosal T cell death is sustainably reverted by infliximab in a caspase dependent pathway in Crohn's disease. Gut 53 (2004) 70-77
85. Van den Brande J.M., Koehler T.C., Zelinkova Z., et al. Prediction of antitumour necrosis factor clinical efficacy by real-time visualisation of apoptosis in patients with Crohn's disease. Gut 56 (2007) 509-517
86. Shen C., Assche G.V., Colpaert S., et al. Adalimumab induces apoptosis of human monocytes: a comparative study with infliximab and etanercept. Aliment Pharmacol Ther 21 (2005) 251-258
87. Kirchner S., Holler E., Haffner S., Andreesen R., and Eissner G. Effect of different tumor necrosis factor (TNF) reactive agents on reverse signaling of membrane integrated TNF in monocytes. Cytokine 28 (2004) 67-74
88. Catrina A.I., Trollmo C., af Klint E., et al. Evidence that anti-tumor necrosis factor therapy with both etanercept and infliximab induces apoptosis in macrophages, but not lymphocytes, in rheumatoid arthritis joints: extended report. Arthritis Rheum 52 (2005) 61-72
89. Malaviya R., Sun Y., Tan J.K., et al. Etanercept induces apoptosis of dermal dendritic cells in psoriatic plaques of responding patients. J Am Acad Dermatol 55 (2006) 590-597
90. Tan J.K., Aphale A., Malaviya R., Sun Y., and Gottlieb A.B. Mechanisms of action of etanercept in psoriasis. J Investig Dermatol Symp Proc 12 (2007) 38-45
91. Agnholt J., and Kaltoft K. Infliximab downregulates interferon-gamma production in activated gut T-lymphocytes from patients with Crohn's disease. Cytokine 15 (2001) 212-222
92. Kawashima M., and Miossec P. Effect of treatment of rheumatoid arthritis with infliximab on IFN gamma, IL4, T-bet, and GATA-3 expression: link with improvement of systemic inflammation and disease activity. Ann Rheum Dis 64 (2005) 415-418
93. Nissinen R., Leirisalo-Repo M., Peltomaa R., Palosuo T., and Vaarala O. Cytokine and chemokine receptor profile of peripheral blood mononuclear cells during treatment with infliximab in patients with active rheumatoid arthritis. Ann Rheum Dis 63 (2004) 681-687
94. Haider A.S., Cardinale I.R., Whynot J.A., and Krueger J.G. Effects of etanercept are distinct from infliximab in modulating proinflammatory genes in activated human leukocytes. J Investig Dermatol Symp Proc 12 (2007) 9-15
95. Hamdi H., Mariette X., Godot V., et al. Inhibition of anti-tuberculosis T-lymphocyte function with tumour necrosis factor antagonists. Arthritis Res Ther 8 (2006) R114
96. Daniel T.M., and Debanne S.M. Estimation of the annual risk of tuberculosis infection for white men in the United States. J Infect Dis 175 (1997) 1535-1537
97. Wallis R.S. Mathematical modeling of the cause of tuberculosis during tumor necrosis factor blockade. Arthritis Rheum 58 (2008) 947-952
98. Brewer M.A., Edwards K.M., Palmer P.S., and Hinson H.P. Bacille Calmette-Guerin immunization in normal healthy adults. J Infect Dis 170 (1994) 476-479
99. Mudido P.M., Guwatudde D., Nakakeeto M.K., et al. The effect of bacille Calmette-Guerin vaccination at birth on tuberculin skin test reactivity in Ugandan children. Int J Tuberc Lung Dis 3 (1999) 891-895
100. Behr M.A., Wilson M.A., Gill W.P., et al. Comparative genomics of BCG vaccines by whole-genome DNA microarray. Science 284 (1999) 1520-1523
101. Brock I., Weldingh K., Leyten E.M., Arend S.M., Ravn P., and Andersen P. Specific T-cell epitopes for immunoassay-based diagnosis of Mycobacterium tuberculosis infection. J Clin Microbiol 42 (2004) 2379-2387
102. de Leon D.P., Acevedo-Vasquez E., Alvizuri S., et al. Comparison of an interferon-gamma assay with tuberculin skin testing for detection of tuberculosis (TB) infection in patients with rheumatoid arthritis in a TB-endemic population. J Rheumatol 35 (2008) 776-781
103. Lalvani A., Nagvenkar P., Udwadia Z., et al. Enumeration of T cells specific for RD1-encoded antigens suggests a high prevalence of latent Mycobacterium tuberculosis infection in healthy urban Indians. J Infect Dis 183 (2001) 469-477
104. de Leon D.P., Acevedo-Vasquez E., Sanchez-Torres A., et al. Attenuated response to purified protein derivative in patients with rheumatoid arthritis: study in a population with a high prevalence of tuberculosis. Ann Rheum Dis 64 (2005) 1360-1361
105. Paimela L., Johansson-Stephansson E.A., Koskimies S., and Leirisalo-Repo M. Depressed cutaneous cell-mediated immunity in early rheumatoid arthritis. Clin Exp Rheumatol 8 (1990) 433-437
106. Richards N.M., Nelson K.E., Batt M.D., Hackbarth D., and Heidenreich J.G. Tuberculin test conversion during repeated skin testing, associated with sensitivity to nontuberculous mycobacteria. Am Rev Respir Dis 120 (1979) 59-65
107. Thompson N.J., Glassroth J.L., Snider D.E., and Farer L.S. The booster phenomenon in serial tuberculin testing. Am Rev Respir Dis 119 (1979) 587-597
108. WHO. Anti-tuberculosis drug resistance in the world: report no 4. Geneva: World Health Organization, 2008. WHO/HTM/TB/2008.394. http://www.who.int/tb/publications/2008/drs_report4_26feb08.pdf (accessed Aug 13, 2008).
109. Comstock G.W., Baum C., and Snider D.E. Isoniazid prophylaxis among Alaskan eskimos: a final report of the Bethel isoniazid studies. Am Rev Respir Dis 119 (1979) 827-830
110. Anon. Efficacy of various durations of isoniazid preventive therapy for tuberculosis: five years of follow-up in the IUAT trial. International Union Against Tuberculosis Committee on Prophylaxis. Bull World Health Organ 60 (1982) 555-564
111. Higuchi K., Harada N., Fukazawa K., and Mori T. Relationship between whole-blood interferon-gamma responses and the risk of active tuberculosis. Tuberculosis (Edinb) 88 (2008) 244-248
112. Edwards L.B., Acquaviva F.A., and Livesay V.T. Identification of tuberculous infected: dual tests and density of reaction. Am Rev Respir Dis 108 (1973) 1334-1339
113. Stout J.E. Safety of rifampin and pyrazinamide for the treatment of latent tuberculosis infection. Expert Opin Drug Saf 3 (2004) 187-198
114. Saukkonen J. Rifampin and pyrazinamide for latent tuberculosis infection: clinical trials and general practice. Clin Infect Dis 39 (2004) 566-568
115. Zhang L.X., Tu D.H., He G.X., et al. Risk of tuberculosis infection and tuberculous meningitis after discontinuation of Bacillus Calmette-Guerin in Beijing. Am J Respir Crit Care Med 162 (2000) 1314-1317
116. Kolappan C., Gopi P.G., Subramani R., et al. Estimation of annual risk of tuberculosis infection (ARTI) among children aged 1-9 years in the south zone of India. Int J Tuberc Lung Dis 8 (2004) 418-423
117. Huang F., Wang L., Zhang J., Deng X., Guo J., and Zhang Y. Risk of tuberculosis in a Chinese registry of rheumatoid arthritis and ankylosing spondylitis for tumour necrosis factor-a antagonists. J Rheumatol 9 (2006) 170-174
118. Matsumoto T., Tanaka T., and Kawase I. Infliximab for rheumatoid arthritis in a patient with tuberculosis. N Engl J Med 355 (2006) 740-741
119. Wallis R.S., Kyambadde P., Johnson J.L., et al. A study of the safety, immunology, virology, and microbiology of adjunctive etanercept in HIV-1-associated tuberculosis. AIDS 18 (2004) 257-264
120. Mayanja-Kizza H., Jones-Lopez E.C., Okwera A., et al. Immunoadjuvant therapy for HIV-associated tuberculosis with prednisolone: a phase II clinical trial in Uganda. J Infect Dis 191 (2005) 856-865
121. Wallis R.S. Reconsidering adjuvant immunotherapy for tuberculosis. Clin Infect Dis 41 (2005) 201-208
122. Karakousis P.C., Yoshimatsu T., Lamichhane G., et al. Dormancy phenotype displayed by extracellular Mycobacterium tuberculosis within artificial granulomas in mice. J Exp Med 200 (2004) 647-657
123. Arend S.M., Leyten E.M., Franken W.P., Huisman E.M., and van Dissel J.T. A patient with de novo tuberculosis during anti-tumor necrosis factor-alpha therapy illustrating diagnostic pitfalls and paradoxical response to treatment. Clin Infect Dis 45 (2007) 1470-1475
124. Garcia Vidal C., Fernandez S.R., Lacasa J.M., Salavert M., Carballeira M.R., and Garau J. Paradoxical response to anti-tuberculous therapy in infliximab-treated patients with disseminated tuberculosis. Clin Infect Dis 40 (2005) 756-759
125. Blackmore T.K., Manning L., Taylor W., and Wallis R.S. Therapeutic use of infliximab in tuberculosis to control severe paradoxical reaction of the brain and lymph nodes. Clin Infect Dis (2008) (in press).